- Records
- 19
- Recruiting
- 11
- Recruiting sites
- 613
- Countries
- 18
ClinicalTrials.gov registry snapshot / 2026-07-24Peptide trials,
Peptide trials,
without the maze.
Search every official registry record matched to 13 tracked peptide and next-generation weight-loss programs. Find current status, phase, enrollment, countries, US states, recruiting cities, postal areas, completion timing, and the direct NCT source.
268unique NCT records
13named programs
53countries represented
1,840recruiting cities
11registry result modules
Recruiting footprint by program
Study status is not drug rank.
Bar length shows registry-listed sites individually marked Recruiting. Larger programs can create larger counts. This does not compare efficacy, safety, approval odds, sponsor quality, or enrollment availability.
- Records
- 52
- Recruiting
- 10
- Recruiting sites
- 170
- Countries
- 7
- Records
- 37
- Recruiting
- 10
- Recruiting sites
- 73
- Countries
- 3
- Records
- 24
- Recruiting
- 10
- Recruiting sites
- 935
- Countries
- 28
- Records
- 27
- Recruiting
- 6
- Recruiting sites
- 1,581
- Countries
- 36
- Records
- 30
- Recruiting
- 5
- Recruiting sites
- 155
- Countries
- 6
- Records
- 8
- Recruiting
- 4
- Recruiting sites
- 339
- Countries
- 23
- Records
- 31
- Recruiting
- 3
- Recruiting sites
- 774
- Countries
- 34
- Records
- 15
- Recruiting
- 3
- Recruiting sites
- 3
- Countries
- 1
- Records
- 34
- Recruiting
- 2
- Recruiting sites
- 450
- Countries
- 27
- Records
- 9
- Recruiting
- 2
- Recruiting sites
- 4
- Countries
- 3
- Records
- 9
- Recruiting
- 1
- Recruiting sites
- 8
- Countries
- 1
- Records
- 5
- Recruiting
- 0
- Recruiting sites
- 0
- Countries
- 0
Official registry finder
Filter the exact records.
Search names, former codes, NCT IDs, sponsors, interventions, conditions, cities, and postal codes. Filtered URLs are shareable but intentionally excluded from search indexing so this page remains the canonical source.
21matching registry records
Matching recruiting site observations68
| Program and record | Status | Phase and enrollment | Locations | Primary completion | Registry update | Source |
|---|---|---|---|---|---|---|
| AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight LossNCT07503210 / AMAZE 12 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 3600 estimated | 4 matching recruitingBorn, Limburg, 6121 XK, Netherlands / 's-Hertogenbosch, North Brabant, 5223 LA, Netherlands / Almere Stad, 1311RL, Netherlands / 1 more area | Jun 6, 2028estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT07503210 ↗ |
| A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityNCT07567001 / HF-POLARIS / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 35,610 estimated | 8 matching recruiting's-Hertogenbosch, 5223 GZ, Netherlands / Dirksland, 3247 BW, Netherlands / Ede, 6716 RP, Netherlands / 5 more areas | Jul 23, 2029estimated | Jul 15, 2026ClinicalTrials.gov | Open NCT07567001 ↗ |
| A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightNCT07253285 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 3460 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Mar 20, 2030estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07253285 ↗ |
| A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightNCT07564414 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 32,500 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Feb 23, 2028estimated | Jul 8, 2026ClinicalTrials.gov | Open NCT07564414 ↗ |
| A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 DiabetesNCT07351045 / Enith1 / Hoffmann-La Roche | RecruitingVerified 2026-07 | Phase 32,000 estimated | 2 matching recruitingNijmegen, 6525 GA, Netherlands / Utrecht, 3584 CX, Netherlands | Jul 24, 2028estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT07351045 ↗ |
| Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityNCT07037433 / MARITIME-CV / Amgen | RecruitingVerified 2026-07 | Phase 312,800 estimated | 30 matching recruitingAlkmaar, 1815 JD, Netherlands / Almelo, 7609 PP, Netherlands / Almere Stad, 1311 RL, Netherlands / 26 more areas | Jun 30, 2028estimated | Jul 24, 2026ClinicalTrials.gov | Open NCT07037433 ↗ |
| Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityNCT07037459 / MARITIME-HF / Amgen | RecruitingVerified 2026-06 | Phase 35,056 estimated | 16 matching recruitingAmsterdam, 1081 HV, Netherlands / Arnhem, 6815 AD, Netherlands / Breda, 4818 CK, Netherlands / 13 more areas | Jun 30, 2028estimated | Jul 2, 2026ClinicalTrials.gov | Open NCT07037459 ↗ |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)NCT07165028 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 34,500 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Aug 2030estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07165028 ↗ |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver FibrosisNCT06632444 / Boehringer Ingelheim | RecruitingVerified 2026-07 | Phase 31,800 estimated | 5 matching recruitingAmsterdam, 1081HV, Netherlands / Dordrecht, 3318 AT, Netherlands / Nijmegen, 6525 GA, Netherlands / 2 more areas | Dec 27, 2031estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT06632444 ↗ |
| LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have CirrhosisNCT06632457 / Boehringer Ingelheim | RecruitingVerified 2026-07 | Phase 31,590 estimated | 3 matching recruitingDordrecht, 3318 AT, Netherlands / Rotterdam, 3015 GD, Netherlands / Schiedam, 3118 JH, Netherlands | Jun 5, 2029estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT06632457 ↗ |
| A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightNCT05567796 / REDEFINE 1 / Novo Nordisk A/S | Active, not recruitingVerified 2026-07 | Phase 33,400 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Oct 30, 2024actual | Jul 17, 2026ClinicalTrials.gov | Open NCT05567796 ↗ |
| REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsNCT05669755 / REDEFINE 3 / Novo Nordisk A/S | Active, not recruitingVerified 2026-07 | Phase 37,101 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Sep 1, 2027estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT05669755 ↗ |
| The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390 / Eli Lilly and Company | Active, not recruitingVerified 2026-07 | Phase 310,000 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Feb 2029estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT06383390 ↗ |
| A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the LiverNCT05202353 / Boehringer Ingelheim | Active, not recruitingVerified 2026-07 | Phase 129 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Dec 2, 2026estimated | Jul 22, 2026ClinicalTrials.gov | Open NCT05202353 ↗ |
| Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver DiseaseNCT06409130 / Novo Nordisk A/S | CompletedVerified 2026-03 | Phase 2270 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Nov 21, 2025actual | Mar 12, 2026ClinicalTrials.gov | Open NCT06409130 ↗ |
| A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose WeightNCT04667377 / Boehringer Ingelheim | CompletedVerified 2023-10Registry results posted | Phase 2387 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Sep 15, 2022actual | Nov 2, 2023ClinicalTrials.gov | Open NCT04667377 ↗ |
| A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)NCT04771273 / Boehringer Ingelheim | CompletedVerified 2024-11Registry results posted | Phase 2295 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Nov 9, 2023actual | Dec 3, 2024ClinicalTrials.gov | Open NCT04771273 ↗ |
| A Study in Healthy Men to Test How BI 456906 is Processed in the BodyNCT05421338 / Boehringer Ingelheim | CompletedVerified 2022-12 | Phase 16 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Nov 17, 2022actual | Dec 14, 2022ClinicalTrials.gov | Open NCT05421338 ↗ |
| A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightNCT06066515 / SYNCHRONIZE™-1 / Boehringer Ingelheim | CompletedVerified 2026-03 | Phase 3726 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Dec 2, 2025actual | Mar 12, 2026ClinicalTrials.gov | Open NCT06066515 ↗ |
| A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose WeightNCT06066528 / SYNCHRONIZE™-2 / Boehringer Ingelheim | CompletedVerified 2026-06 | Phase 3755 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Dec 12, 2025actual | Jun 24, 2026ClinicalTrials.gov | Open NCT06066528 ↗ |
| A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)NCT06077864 / Boehringer Ingelheim | CompletedVerified 2026-07 | Phase 35,531 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jun 1, 2026actual | Jul 23, 2026ClinicalTrials.gov | Open NCT06077864 ↗ |
Recruiting location footprint
Country and US state routes.
Counts are site observations across registry records, not unique facilities. The same research center can appear in multiple studies. Open the exact NCT record before treating a location as current.
Clinical trial finder FAQ
Status, location, and enrollment are different fields.
These answers prevent the most common registry-search errors before a reader follows an official source.
Are any Retatrutide clinical trials recruiting?
Yes. This 2026-07-24 snapshot contains 2 Retatrutide registry records with an overall Recruiting status and 450 listed sites individually marked Recruiting. Overall status does not mean every site is open, and neither status establishes eligibility or enrollment. Open the exact NCT record and verify the individual location before contacting a study team.
How do I find a peptide clinical trial near me?
Enter a city or postal code, optionally add a country or US state, and then open the exact ClinicalTrials.gov record. This finder retains location rows individually marked Recruiting but omits facility and personal contact fields. Confirm current recruitment, eligibility, official contact route, and travel requirements on the registry. Peptide Local does not enroll participants.
Does Recruiting mean I can join the trial?
No. Recruiting is a registry status, not an eligibility decision or appointment. A study can be recruiting overall while some listed locations are not yet recruiting, active but closed, completed, suspended, or missing a current site status. The study team applies the protocol's eligibility and consent process.
Are the drugs in this clinical trial finder FDA approved?
A ClinicalTrials.gov record is not FDA approval. The finder covers investigational programs and can also include studies involving components or comparators with separate regulatory histories. Approval must be verified on the exact FDA label or regulator record, not inferred from a phase, sponsor, trial result, or recruiting status.
Why do only some registry records show posted results?
11 of 268 records in this snapshot expose a ClinicalTrials.gov results module. A record without posted registry results can still have a publication or sponsor announcement elsewhere, while a posted module still requires careful interpretation. Results availability is not a quality rank.
How current is the peptide clinical trial data?
The registry data timestamp is July 24, 2026 at 9:00 AM UTC. The refresh workflow searches exact intervention names and aliases, deduplicates by NCT ID, preserves multi-program studies, and stores overall and individual-site status separately. Registry fields can change after that timestamp, so the direct source remains authoritative for enrollment decisions.
Evidence boundary
A registry finder, not an enrollment service.
A dated transformation of ClinicalTrials.gov intervention-search records for thirteen named Peptide Local pipeline programs. Study sponsors or investigators submit and maintain registry records. Overall status, individual-site status, enrollment, locations, completion dates, and results availability can change. Recruiting status does not establish eligibility, enrollment, treatment access, regulatory approval, routine availability, or a favorable benefit-risk conclusion.
Peptide Local omits personal contact details and does not screen participants, recommend a protocol, interpret eligibility, arrange treatment, or authenticate commercial products that reuse an investigational program's name.
Read the official API documentation ↗Understand evidence categories →